Risk adjusted net present value: What is the current valuation of Enliven Therapeutics’s ELVN-002?

ELVN-002 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Cognitive behavioral therapy enhances the mental well-being and life quality of cancer patients

The impact of cognitive-behavioral treatment on the mental health and quality of life of cancer patients.

August 23, 2024

Podcast: New online tool helps young people better manage Crohn’s disease

Aston University’s Dr Cassie Screti joined the latest Aston Originals Health Matters podcast recorded for World Inflammatory Bowel Disease Day to discuss a new online

May 17, 2024

U.S. Suspends Wuhan Lab Funding; ‘Zombie’ Clinical Trials; Wachter’s COVID Scare

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week. U.S. Suspends Wuhan Lab’s Funding The

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.